A popular obesity drug may help treat a dangerous disorder in which people struggle to breathe while they sleep, a new study finds. Tirzepatide, the medication in the weight loss drug Zepbound and ...

Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

A popular weight loss drug may be able to assist in the treatment of sleep apnea, a new study found. Tirzepatide, the medicine found in the drug Zepbound and the obesity drug Mounjaro, reduced the … ...

But the program may be able to cover an obesity medication that treats a secondary condition, like obstructive sleep apnea. Scientists are studying weight loss drugs for a broad array of ...

The Food and Drug Administration ... Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to treat patients ...

Zepbound was approved last year to treat obesity. The drug's maker, Eli Lilly, says it reduces the severity of obstructive sleep apnea by 63%.

A popular weight loss drug may be able to assist in the treatment of sleep apnea, a new study found. Tirzepatide, the medicine found in the drug Zepbound and the obesity drug Mounjaro, reduced the ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep apnea. The FDA’s decision may place added pressure on insurance companies to cover obesity ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the ...